Afficher la couverture 'Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial | Waters, Laura' en grand format
/5

0 avis

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial

Archive ouverte

Waters, Laura | Assoumou, Lambert | González-Cordón, Ana | Rusconi, Stefano | Domingo, Pere | Gompels, Mark | de Wit, Stephane | Raffi, François | Stephan, Christoph | Masiá, Mar | Rockstroh, Jürgen | Katlama, Christine | Behrens, Georg | Moyle, Graeme | Johnson, Margaret | Fox, Julie | Stellbrink, Hans-Jürgen | Guaraldi, Giovanni | Florence, Eric | Esser, Stefan | Gatell, Jose, M | Pozniak, Anton | Martínez, Esteban

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Switching from boosted protease inhibitors to dolutegravir in persons with HIV with igh cardiovascular risk led to modest weight increases limited to the first 48 weeks that did not differ from those reported in the general population after 96 weeks.

Suggestions

Du même auteur

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Archive ouverte | González-Cordón, Ana | CCSD

International audience. Background: Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether this str...

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

Archive ouverte | Gatell, José | CCSD

International audience. BackgroundBoth immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)–based regimen to a dolutegravir (DTG)–based regimen may improve lipid profile.MethodsEuropea...

Switching from a Ritonavir-Boosted Protease Inhibitor to a Dolutegravir-Based Regimen for Maintenance of HIV Viral Suppression in Patients with High Cardiovascular Risk

Archive ouverte | Gatell, Jose M. | CCSD

International audience. Objective: To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen.Methods: HIV type 1-i...

Chargement des enrichissements...